US Content
-
FinCEN moves to activate whistleblower rewards framework
A proposed rule would turn long-standing statutory promises into a functioning system.
-
Three March SEC cases highlight investor protection
A brief enforcement roundup.
-
FDA to consider relaxing restrictions for peptides
The regulator said it is looking to take seven peptides off a restrictive list for unapproved drugs considered too risky.
-
Fake it ’til you make it: Study finds nearly half of health-related AI responses ‘problematic’
Researchers are concerned by the confident tone generative AI models use in their responses, considering their lack of credentials.
-
Shadow AI: What AI meeting note-takers mean for regulated industries
It’s the AI problem hiding in plain sight, says Manuela Bárcenas.
-
CHECKLIST: Is your AI meeting note-taker compliant?
A security checklist for regulated Industries.
-
Podiatrist, pharma rep sentenced to 63 months for healthcare fraud
In a case involving an unlicensed person performing medical procedures on unwitting patients, the two California men billed state and federal programs $3.2m in false claims.
-
As the SEC steps back on rulemaking, advisers face different compliance challenges
The agency’s less prescriptive approach may give firms more uncertainty, Janaya Moscony of SEC³ Compliance tells us.